Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial

Antonio Cascio, Claudia Colomba, Lucina Titone Lanza Di Scalea, Claudia Colomba, Lucina Titone, Spinello Antinori, Antonio Cascio, David L. Paterson

Risultato della ricerca: Articlepeer review

54 Citazioni (Scopus)

Abstract

We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (+/- standard deviation) was 46.2+/-36.4 h in the clarithromycin group and 39.3+/-31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromycin and azithromycin could be acceptable therapeutic alternatives to chloramphenicol and tetracyclines for children aged < or =8 years with Mediterranean spotted fever. Azithromycin, because it has a long half-life, offers the advantages of administration in a single daily dose and a shorter duration of therapy, which could increase compliance in children
Lingua originaleEnglish
pagine (da-a)154-158
Numero di pagine5
RivistaClinical Infectious Diseases
Volume34
Stato di pubblicazionePublished - 2002

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2726???
  • ???subjectarea.asjc.2700.2725???

Fingerprint

Entra nei temi di ricerca di 'Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial'. Insieme formano una fingerprint unica.

Cita questo